1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: Is Esperion's ETC-1002 a viable threat to the PCSK9 inhibitors if mid-stage data are replicated in Phase III studies?

Physician Views: Is Esperion's ETC-1002 a viable threat to the PCSK9 inhibitors if mid-stage data are replicated in Phase III studies?

  • March 2015
  • ID: 3509577
  • Format: PDF
  • By Firstword Pharma

Summary






Last week saw Esperion Therapeutics release promising Phase IIb data for its oral hypercholesterolaemia treatment ETC-1002. When added to stable statin therapy, a 180mg dose of ETC-1002 demonstrated a 24 percent incremental reduction in LDL-cholesterol versus those patients treated only with a statin, while a lower 120mg dose demonstrated a 17 percent reduction in LDL-C.

Although some way below the approximately 60 percent LDL-C reductions demonstrated by the PCSK9 inhibitors (Amgen's Repatha and Regeneron Pharmaceuticals/Sanofi's Praluent), which are widely expected to reach the US market in the second half of 2015, the efficacy of ETC-1002 – if replicated in larger Phase III studies – could represent a threat to these injectable and (presumed) more costly treatments.

The PCSK9s are forecast to gain steady traction in certain patients, such as those with heterozygous familial hypercholesterolaemia (HeFH), but uptake in the broader statin population will be necessary if top-end forecasts are to be reached.

With payers having already called out the likely high price of the PCSK9 class, and with cardiologists recently polled by FirstWord noting that statin use remains sub-optimal, Esperion stands more than a glimmer of a chance to establish ETC-1002 in the treatment paradigm – potentially ahead of the PCSK9s – in patients who are completely intolerant to statins or intolerant to higher doses of statin therapy – if Phase III studies can produce comparable data to that generated in mid-stage studies.

Esperion CEO Tim Mayleben was in a bullish frame of mind as data for ETC-1002 broke last week, proclaiming the drug to represent a "patient friendly, physician friendly and payer friendly approach" to expanding the treatment of hypercholesterolaemia beyond the statin class.

Much depends on clinical progression of the compound over the next few years, the role of regulators (in determining when – i.e. pre/post-launch – cardiovascular outcomes data will be required) and potential out-licensing of ETC-1002 to support these developments.








Nevertheless, even at this stage of development – and with the positioning of the PCSK9s still under much discussion – we are polling US and EU5 cardiologists to gauge their sentiment towards Phase IIb data for ETC-1002 and their potential usage should comparable data be produced in larger Phase III studies. Specifically we are asking them…




If comparable efficacy data were demonstrated in Phase III studies – and ETC-1002 was priced on par with a branded statin – to what percentage of patients already receiving a statin would you also prescribe ETC-1002?
If comparable efficacy data were demonstrated in Phase III studies, would you consider prescribing ETC-1002 ahead of a PCSK9 inhibitor to patients with uncontrolled LDL-C who are unable to tolerate higher statin doses?
If comparable efficacy data were demonstrated in Phase III studies, would you consider prescribing ETC-1002 ahead of a PCSK9 inhibitor to patients who are unable to tolerate any statin therapy?
If comparable data were demonstrated for ETC-1002 in Phase III studies, how significant a barrier to uptake would this product be in limiting/slowing use of the emerging PCSK9 inhibitor class?
Based on the available data for ETC-1002 (and assuming comparable replication in Phase III) and LDL-C reduction demonstrated by the PCSK9 inhibitor class (approximately 60 percent), what impact would moderately positive cardiovascular outcomes data for the PCSK9 inhibitors have in limiting the use of ETC-1002?





Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2019

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Pipeline ...

Dyslipidemia Global Clinical Trials Review, H2, 2019

Dyslipidemia Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Dyslipidemia Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Dyslipidemia Global Clinical Trials Review, H2, 2019" provides an overview of Dyslipidemia clinical trials scenario.This ...

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global ...

Wounds - Pipeline Review, H2 2019 $ 2000 December 2019


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on